Source:http://linkedlifedata.com/resource/pubmed/id/18172953
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2008-1-3
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
1533-4406
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:day |
3
|
| pubmed:volume |
358
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
92; author reply 92-3
|
| pubmed:meshHeading |
pubmed-meshheading:18172953-Amyloidosis,
pubmed-meshheading:18172953-Dexamethasone,
pubmed-meshheading:18172953-Drug Therapy, Combination,
pubmed-meshheading:18172953-Humans,
pubmed-meshheading:18172953-Immunoglobulin Light Chains,
pubmed-meshheading:18172953-Melphalan,
pubmed-meshheading:18172953-Myeloablative Agonists,
pubmed-meshheading:18172953-Research Design
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
|
| pubmed:publicationType |
Letter,
Comment
|